ADVERTISEMENT
Advances in Treatment Options for Patients With T-Cell Lymphoma
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, University of Nebraska Medical Center, Omaha, Nebraska discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
Transcript:
I'm Dr. Julie Vose from the University of Nebraska Medical Center, where I'm the Chief of Hematology-Oncology. My specialty is doing research and studying patients with non-Hodgkin lymphoma.
Today my talk was related to an unusual type of T-cell lymphoma, peripheral T-cell lymphoma, and the classification for that we now know has many different subtypes within that T-cell lymphoma classification. Research has been done for several years now. We did a very large international study starting in early 2000, looking at the outcomes for these patients and found that with standard therapy such as CHOP therapy, unfortunately the outcomes are very poor, with only about 10% of patients living long-term, past 5 to 10 years.
So, as we understand more and more the subtypes of T-cell lymphoma, we can understand the pathways and improve our treatments for those patients. We're trying to look at different subtypes of peripheral T-cell lymphoma by gene expression profiling and understand that the GATA 3 versus TBX21 subtypes have different genes that we may be able to target with future therapies.
Most recently, the most successful therapies for T-cell lymphoma have been brentuximab vedotin targeting CD30, which has improved single-agent, but also combination outcomes for our patients that are CD30-positive.
For T-cell lymphomas that are CD30-negative, we still have, unfortunately, very poor outcomes for the majority of our patients and need to develop new therapies. So, some of the pathways that we're currently looking at with these new therapies would be subtypes within those subtypes of lymphoma that I discussed earlier, and trying to look at methylation agents. Looking at EZH2 agents, looking at azacitidine or looking at decitabine, to try to target those specific pathways in different types of T-cell lymphomas.
We have a long way to go, but we need to work together on clinical trials going forward to enroll these patients as they're very difficult to treat with standard of therapies. Thank you.
Source:
Vose J. T-Cell Lymphomas – How Can We Improve Outcomes Beyond CHOP? Presented at Lymphoma, Leukemia & Myeloma Congress; October 18-21, 2023. New York, NY
